Doctors, Drug Companies, and Conflicts of Interest
This paper examines the ethically problematic relationship between physicians and pharmaceutical companies in the United States. Drawing on peer-reviewed sources from the New England Journal of Medicine and the British Medical Journal, the paper argues that pharmaceutical marketing — through gifts, free meals, sponsored conferences, and research funding — measurably alters doctors' prescribing habits in ways that harm patients. The paper critiques the Affordable Care Act's Sunshine Law as insufficient, highlights the denial among physicians regarding industry influence, and calls for comprehensive legislative reform modeled on conflict-of-interest bans adopted by select academic medical centers. The broader argument situates these conflicts within a for-profit health care system that consistently prioritizes corporate profits over patient welfare.
- The For-Profit Health Care Problem: ACA's limits and for-profit system critique
- How Pharmaceutical Marketing Influences Physicians: Marketing tactics that alter prescribing habits
- Physician Denial and the Limits of Transparency Laws: Doctors deny influence; Sunshine Law falls short
- The Scale and Scope of Industry Payments: Dollar amounts and breadth of payments to doctors
- Industry Arguments and Their Flaws: Pro-industry claims examined and refuted
- The Case for Comprehensive Legislative Reform: Legislative bans as the necessary solution
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper grounds its argument in peer-reviewed empirical sources (British Medical Journal, New England Journal of Medicine), giving its ethical claims measurable evidentiary support — for example, citing the $19 billion pharmaceutical companies spend annually on physician relationships as direct proof of marketing's impact on prescribing behavior.
- It anticipates and systematically refutes counterarguments, addressing industry claims about "under-prescribed" medications and physician education before dismissing them as pretexts for profit-driven marketing.
- The paper maintains a consistent evaluative lens — the for-profit health care model — that unifies all its specific claims into a coherent overarching critique.
Key academic technique demonstrated
The paper effectively uses source synthesis to build a cumulative argument. Rather than treating each source in isolation, it layers findings from Moynihan (2003), Campbell (2007), and Carollo (2010) so that each successive citation reinforces and deepens the previous one, moving from evidence of behavioral influence to statistical scale to policy failure. This stacking technique strengthens the argument's overall persuasive weight.
Structure breakdown
The paper opens with a macro-level critique of the for-profit health care system, narrows to the specific doctor-pharmaceutical relationship, documents its empirical harms and the culture of denial surrounding them, assesses current legislative attempts as inadequate, dismantles pro-industry arguments, and concludes with a concrete reform proposal. This funnel structure — broad systemic critique → specific evidence → policy response — is a reliable model for health policy argumentative writing.
The For-Profit Health Care Problem
Although the Affordable Care Act represents a step in the right direction toward encouraging all Americans to access medical services, it fails to address the root causes of the system's problems. The American health care system is flawed because it operates as a for-profit model that places financial gain far ahead of patients. When profits take precedence over patients, health care workers become unable to fulfill their ethical duties. A progressive transformation of the American health care system would systematically undo the harmful link between corporate interests and the interests of patient care.
How Pharmaceutical Marketing Influences Physicians
The relationship between doctors and drug companies has been well established and well documented. Major news outlets such as The Atlantic, as well as peer-reviewed journals like the New England Journal of Medicine, have covered the ethical conundrums inherent in the close relationship between physicians and pharmaceutical companies. Shaywitz (2013) described the problem as involving "a bunch of nefarious pushers who pay off vulnerable doctors to prescribe their latest expensive, mediocre product," while still defending the special relationship that has developed between doctors and pharmaceutical manufacturers. However, Shaywitz's (2013) argument rests on opinion and conjecture rather than evidence.
Most established professional journals indicate that collusion between doctors and drug companies produces a range of problems that potentially harm patients. Writing for the British Medical Journal, Moynihan (2003) presents empirical evidence showing that doctors' prescribing habits change measurably after exposure to the skillful marketing techniques used by pharmaceutical industry representatives — techniques ranging from free dinners to gifts. Specifically, doctors' prescribing habits become "less appropriate" following such exposure, including "a rise in both prescription expenditures and irrational and incautious prescribing, according to a recent analysis of the ethics of gift giving" (Moynihan, 2003, p. 1189).
Create your account
Always verify citation format against your institution’s current style guide requirements.